NCT07807943 Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population
| NCT ID | NCT07807943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Observational Study |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-08-26 |
| Primary Completion | 2028-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-08-26 with a primary completion date of 2028-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample \>10-year survivors.
Eligibility Criteria
Inclusion Criteria 1. Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy 2. Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment 3. Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications 4. Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference 5. Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center Exclusion Criteria * Active joint infection or suspected septic arthritis * Life expectancy \<6 months * Prior knee arthroplasty in the index knee * Coagulopathy or contraindications to angiography * GFR \<30 mL/min/1.73m² * Peripheral artery disease with stenosis or occlusion of lower extremity vasculature (relative contraindication per SIR standards, given geniculate artery collateral perfusion role) * Radiographically normal knee joint (KL grade 0-1) - alternative etiologies should be sought * Known active autoimmune/inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis) * Any medical condition or clinical abnormality that, per investigator judgment, precludes safe participation in and completion of the study
Contact & Investigator
Nicolas J Cardenas, MD
PRINCIPAL INVESTIGATOR
UT MD Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07807943 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Observational Study. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07807943 currently recruiting?
Yes, NCT07807943 is actively recruiting participants. Contact the research team at NJCardenas@mdanderson.org for enrollment information.
Where is the NCT07807943 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07807943 clinical trial?
NCT07807943 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Nicolas J Cardenas, MD at UT MD Anderson Cancer Center. The trial plans to enroll 50 participants.